RU2000122733A - 1,3,4-OXADIAZOLONE DERIVATIVES - Google Patents
1,3,4-OXADIAZOLONE DERIVATIVESInfo
- Publication number
- RU2000122733A RU2000122733A RU2000122733/04A RU2000122733A RU2000122733A RU 2000122733 A RU2000122733 A RU 2000122733A RU 2000122733/04 A RU2000122733/04 A RU 2000122733/04A RU 2000122733 A RU2000122733 A RU 2000122733A RU 2000122733 A RU2000122733 A RU 2000122733A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- methyl
- oxadiazol
- chloro
- dihydro
- Prior art date
Links
- WTSXVIMLKCKWIW-UHFFFAOYSA-N 3H-1,3,4-oxadiazol-2-one Chemical class O=C1NN=CO1 WTSXVIMLKCKWIW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 230000003000 nontoxic Effects 0.000 claims 4
- 231100000252 nontoxic Toxicity 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- -1 4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenyl (dimethylamino) Chemical class 0.000 claims 2
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 claims 2
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 claims 2
- 206010018987 Haemorrhage Diseases 0.000 claims 2
- 206010061255 Ischaemia Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010070976 Craniocerebral injury Diseases 0.000 claims 1
- 206010015037 Epilepsy Diseases 0.000 claims 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 210000000278 Spinal Cord Anatomy 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- SUGURSDJQFUZOY-UHFFFAOYSA-M [2-[4-chloro-2-[[2-oxo-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-3-yl]methyl]phenoxy]-2-oxoethyl]-trimethylazanium;methanesulfonate Chemical compound CS([O-])(=O)=O.C[N+](C)(C)CC(=O)OC1=CC=C(Cl)C=C1CN1C(=O)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 SUGURSDJQFUZOY-UHFFFAOYSA-M 0.000 claims 1
- LUEVZKJWSNNTRM-UHFFFAOYSA-M [2-[[4-chloro-2-[[2-oxo-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-3-yl]methyl]phenoxy]methoxy]-2-oxoethyl]-trimethylazanium;methanesulfonate Chemical compound CS([O-])(=O)=O.C[N+](C)(C)CC(=O)OCOC1=CC=C(Cl)C=C1CN1C(=O)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 LUEVZKJWSNNTRM-UHFFFAOYSA-M 0.000 claims 1
- ZXVRACRVVBWHBP-UHFFFAOYSA-N [4-chloro-2-[[2-oxo-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-3-yl]methyl]phenyl] 2-(dimethylamino)ethyl carbonate Chemical compound CN(C)CCOC(=O)OC1=CC=C(Cl)C=C1CN1C(=O)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 ZXVRACRVVBWHBP-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- ZJEZSISCHHJCIO-UHFFFAOYSA-N methyl 4-(dimethylamino)butanoate Chemical compound COC(=O)CCCN(C)C ZJEZSISCHHJCIO-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 201000007196 sexual disease Diseases 0.000 claims 1
Claims (16)
где А обозначает простую связь или -СН2О-;
В обозначает простую связь или кислород;
D обозначает -(СН2)n- или -СН2СНОНСН2-;
n - целое число от 1 до 4;
R обозначает -NR1R2 или -NR1R2R3X, где Х обозначает противоион;
R1, R2 и R3 каждый независимо обозначает водород или С1-4 алкил,
или его нетоксичные фармацевтически приемлемые соль или сольват.1. The compound of the formula
where a denotes a simple bond or-CH 2 O-;
B is a single bond or oxygen;
D denotes - (CH 2 ) n - or -CH 2 CHONSN 2 -;
n is an integer from 1 to 4;
R is —NR 1 R 2 or —NR 1 R 2 R 3 X, where X is a counterion;
R 1 , R 2 and R 3 each independently represents hydrogen or C 1-4 alkyl,
or a non-toxic pharmaceutically acceptable salt or solvate thereof.
4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] -метил] фенил(диметиламино)ацетат;
4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] -метил] фенил-3-(диметиламино)пропионат;
4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] -метил] фенил-4-(диметиламино)бутират;
[[[4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] метил] фенокси] карбонил] метил] триметиламмонийметансульфонат;
2-[[[4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] метил] фенокси] карбонил] этил] диэтилметиламмонийметансульфонат;
3-[[[4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] метил] фенокси] карбонил] пропил] триметиламмонийметансульфонат;
4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] -метил] фенил(метиламино)ацетат и
4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] -метил] фенил-3-аминопропионат;
или их нетоксичные фармацевтически приемлемые соль, противоион или сольват.3. The compound according to claim 2, characterized in that it is selected from the group including
4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenyl (dimethylamino) acetate;
4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenyl-3- (dimethylamino a) propionate;
4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenyl-4- (dimethylamino a) butyrate;
[[[4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenoxy] carbonyl] methyl] trimethylammonium methane sulfonate;
2 - [[[4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenoxy] carbonyl] ethyl] diethylmethylammonium methane sulfonate;
3 - [[[4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenoxy] carbonyl] propyl] trimethylammonium methanesulfonate;
4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenyl (methylamino) acetate and
4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenyl-3-aminopropionate;
or a non-toxic pharmaceutically acceptable salt, counterion or solvate thereof.
3-[[5-хлор-2-[[[[2-(диметиламино)этил] окси] карбонил] окси] фенил] метил] -5-[4-(три-фторметил)фенил] -1,3,4-оксадиазол-2(3Н)-он,
2-[[[[4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] метил] фенокси] карбонил] окси] этил] триметиламмонийметансульфонат,
или их нетоксичные фармацевтически приемлемые соль, противоион или сольват.5. The compound according to claim 4, selected from the group including
3 - [[5-chloro-2 - [[[[2- (dimethylamino) ethyl] oxy] carbonyl] oxy] phenyl] methyl] -5- [4- (tri-fluoromethyl) phenyl] -1.3,4 -oxadiazol-2 (3H) -one,
2 - [[[[4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenoxy ] carbonyl] oxy] ethyl] trimethylammonium methanesulfonate,
or a non-toxic pharmaceutically acceptable salt, counterion or solvate thereof.
[4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] -метил] фенокси] метил-4-(диметиламино)бутират;
3-[[[[4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] метил] фенокси] метокси] карбонил] пропил] триметиламмонийметансульфонат;
[[[[4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] метил] фенокси] метокси] карбонил] метил] триметиламмонийметансульфонат; и
[4-хлор-2-[[5-[4-(трифторметил)фенил] -2,3-дигидро-2-оксо-1,3,4-оксадиазол-3-ил] -метил] фенокси] метил-3-(диэтиламино)пропианата гидрохлорид,
или их нетоксичные фармацевтически приемлемые соль, противоион или сольват.7. The compound according to claim 4, selected from the group including
[4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenoxy] methyl-4 - (dimethylamino) butyrate;
3 - [[[[4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenoxy ] methoxy] carbonyl] propyl] trimethylammonium methanesulfonate;
[[[[4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenoxy] methoxy ] carbonyl] methyl] trimethylammonium methane sulfonate; and
[4-chloro-2 - [[5- [4- (trifluoromethyl) phenyl] -2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl] methyl] phenoxy] methyl-3 - (diethylamino) propionate hydrochloride,
or a non-toxic pharmaceutically acceptable salt, counterion or solvate thereof.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7296698P | 1998-01-29 | 1998-01-29 | |
US60/072,966 | 1998-01-29 | ||
US10227498P | 1998-09-29 | 1998-09-29 | |
US60/102,274 | 1998-09-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000122733A true RU2000122733A (en) | 2002-08-10 |
RU2202548C2 RU2202548C2 (en) | 2003-04-20 |
Family
ID=26753969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000122733/04A RU2202548C2 (en) | 1998-01-29 | 1999-01-15 | Derivatives of 1,3,4-oxadiazolone, pharmaceutical composition based on thereof and method of treatment |
Country Status (27)
Country | Link |
---|---|
US (1) | US6034113A (en) |
EP (1) | EP1051173A4 (en) |
JP (1) | JP2002527352A (en) |
KR (1) | KR20010077838A (en) |
CN (1) | CN1150175C (en) |
AR (1) | AR010712A1 (en) |
AU (1) | AU735704B2 (en) |
BG (1) | BG104706A (en) |
BR (1) | BR9913010A (en) |
CA (1) | CA2318830A1 (en) |
CO (1) | CO5090837A1 (en) |
EE (1) | EE04089B1 (en) |
GE (1) | GEP20032914B (en) |
HU (1) | HUP0102025A3 (en) |
ID (1) | ID26909A (en) |
IL (1) | IL137518A0 (en) |
LT (1) | LT4838B (en) |
LV (1) | LV12559B (en) |
NO (1) | NO317102B1 (en) |
NZ (1) | NZ505409A (en) |
PL (1) | PL342060A1 (en) |
RU (1) | RU2202548C2 (en) |
SK (1) | SK10852000A3 (en) |
TR (1) | TR200002019T2 (en) |
TW (1) | TW550075B (en) |
UA (1) | UA58579C2 (en) |
WO (1) | WO1999038510A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU736599B2 (en) * | 1998-01-29 | 2001-08-02 | Bristol-Myers Squibb Company | Amino acid derivatives of diaryl 1,3,4-oxadiazolone |
US6297241B1 (en) | 1999-01-29 | 2001-10-02 | Bristol-Myers Squibb Company | Carbamate derivatives of diaryl 1,3,4-oxadiazolone |
EP1150978A4 (en) * | 1999-01-29 | 2002-06-12 | Bristol Myers Squibb Co | Carbamate derivatives of diaryl 1,3,4-oxadiazolone |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
CA2438868A1 (en) | 2001-02-20 | 2002-09-19 | Valentin K. Gribkoff | Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases |
JP4073786B2 (en) * | 2001-04-16 | 2008-04-09 | 田辺三菱製薬株式会社 | High conductance calcium-sensitive K channel opener |
US6909027B1 (en) * | 2001-08-13 | 2005-06-21 | Perry Robins | Method of forming an in-situ film dressing and the composition of the film-forming material |
US7119246B2 (en) * | 2002-06-25 | 2006-10-10 | Perry Robins | Method of treating acne |
EP4356912A2 (en) | 2012-05-16 | 2024-04-24 | Techfields Pharma Co., Ltd. | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
JP5855599B2 (en) * | 2013-04-30 | 2016-02-09 | テックフィールズ バイオケム カンパニー リミテッド | Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate |
CN104710379B (en) * | 2015-03-09 | 2017-01-18 | 华南理工大学 | Synthetic method for BMS-191011 |
JP6165816B2 (en) * | 2015-10-01 | 2017-07-19 | テックフィールズ バイオケム カンパニー リミテッド | Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate |
CN110545809A (en) * | 2017-02-24 | 2019-12-06 | 奥维德医疗公司 | Methods of treating episodic disease |
CN110987847B (en) * | 2019-12-11 | 2021-02-19 | 苏州今蓝纳米科技有限公司 | Application of 1,3, 4-oxadiazole derivative in acid detection and data encryption and storage |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH583213A5 (en) * | 1973-05-21 | 1976-12-31 | Ciba Geigy Ag | |
IT1251488B (en) * | 1991-09-17 | 1995-05-15 | Mini Ricerca Scient Tecnolog | OSSA (TIA) DIAZOL- AND TRIAZOL-ONI (TIONI) WITH ACARICIDE AND INSECTICIDE ACTIVITY |
US5234947A (en) * | 1991-11-07 | 1993-08-10 | New York University | Potassium channel activating compounds and methods of use thereof |
US5547966A (en) * | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
AU736599B2 (en) * | 1998-01-29 | 2001-08-02 | Bristol-Myers Squibb Company | Amino acid derivatives of diaryl 1,3,4-oxadiazolone |
-
1999
- 1999-01-15 SK SK1085-2000A patent/SK10852000A3/en unknown
- 1999-01-15 HU HU0102025A patent/HUP0102025A3/en unknown
- 1999-01-15 RU RU2000122733/04A patent/RU2202548C2/en not_active IP Right Cessation
- 1999-01-15 WO PCT/US1999/000910 patent/WO1999038510A1/en not_active Application Discontinuation
- 1999-01-15 BR BR9913010-6A patent/BR9913010A/en not_active IP Right Cessation
- 1999-01-15 KR KR1020007008227A patent/KR20010077838A/en not_active Application Discontinuation
- 1999-01-15 EE EEP200000447A patent/EE04089B1/en not_active IP Right Cessation
- 1999-01-15 AU AU22308/99A patent/AU735704B2/en not_active Ceased
- 1999-01-15 NZ NZ505409A patent/NZ505409A/en unknown
- 1999-01-15 CA CA002318830A patent/CA2318830A1/en not_active Abandoned
- 1999-01-15 PL PL99342060A patent/PL342060A1/en unknown
- 1999-01-15 ID IDW20001421A patent/ID26909A/en unknown
- 1999-01-15 GE GEAP19995472A patent/GEP20032914B/en unknown
- 1999-01-15 US US09/232,033 patent/US6034113A/en not_active Expired - Fee Related
- 1999-01-15 CN CNB998024112A patent/CN1150175C/en not_active Expired - Fee Related
- 1999-01-15 EP EP99902290A patent/EP1051173A4/en not_active Withdrawn
- 1999-01-15 UA UA2000085059A patent/UA58579C2/en unknown
- 1999-01-15 IL IL13751899A patent/IL137518A0/en unknown
- 1999-01-15 TR TR2000/02019T patent/TR200002019T2/en unknown
- 1999-01-15 JP JP2000529243A patent/JP2002527352A/en active Pending
- 1999-01-27 AR ARP990100312A patent/AR010712A1/en not_active Application Discontinuation
- 1999-01-27 TW TW088101231A patent/TW550075B/en not_active IP Right Cessation
- 1999-01-28 CO CO99004746A patent/CO5090837A1/en unknown
-
2000
- 2000-07-14 LT LT2000068A patent/LT4838B/en not_active IP Right Cessation
- 2000-07-26 NO NO20003825A patent/NO317102B1/en not_active IP Right Cessation
- 2000-08-03 LV LVP-00-103A patent/LV12559B/en unknown
- 2000-08-22 BG BG104706A patent/BG104706A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000122733A (en) | 1,3,4-OXADIAZOLONE DERIVATIVES | |
RU2002118213A (en) | ADAMANTANE DERIVATIVES | |
JP2005515978A5 (en) | ||
JP2004520292A5 (en) | ||
RU2001135801A (en) | Beta2-adrenergic agonists | |
CA2427576A1 (en) | Benzodiazepine derivatives as gaba a receptor modulators | |
US6423709B1 (en) | Methods of using novel compounds as neuro-protective agents | |
RU2005131165A (en) | IMIDAZOLE-4-YLETINYLPYRIDINE DERIVATIVES | |
JP2002539181A5 (en) | ||
RU2318812C2 (en) | Derivatives of isoquinoline | |
US5212169A (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain | |
US6288096B1 (en) | Thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives | |
JP2011510072A5 (en) | ||
JP2003535821A5 (en) | ||
RU98117245A (en) | 2- (ARYLPHENYL) AMINOIMIDASOLINE DERIVATIVES | |
RU2006113942A (en) | DERIVATIVES OF BENZIMIDAZOLONE AND QUINAZOLINE AS ANGONISTS OF HUMAN ORL RECEPTORS | |
EP2382980A3 (en) | Use of Core 2 GlcNac-T inhibitors III for treating vascular complications of diabetes | |
JP2007505105A5 (en) | ||
US6448396B2 (en) | Compounds useful as neuro-protective agents | |
US6579871B2 (en) | Methods of using novel compounds as neuro-protective agents | |
RU2007108410A (en) | FIBER COMPOUNDS WITH ACTIVITY OF PPAR AGONISTS | |
EP0951903B1 (en) | Bis-indolylmaleimides for the therapeutic treatment of renal dysfunction | |
ZA200205801B (en) | Novel use of phenylheteroalkylamine derivatives. | |
RU99118591A (en) | DERIVATIVES 2- (1,2,4-TRIAZOL-1-IL) -1,3,4-TIADIAZOL, RENDERING EFFECT ON THE CENTRAL NERVOUS SYSTEM AND HEART | |
JPWO2021170774A5 (en) |